FINWIRES · TerminalLIVE
FINWIRES

Aurora Cannabis Launching New Medical Cannabis Products Globally

By

-- Aurora Cannabis (ACB.TO) is "significantly" expanding its global medical cannabis portfolio, with product launches rolling out across Canada, Europe and Australia, the company said on Tuesday.

The newly expanded lineup includes dried flower, pre-rolls and pastilles, and will be rolled out between now and June, a statement added.

"By expanding our offerings in key countries, we're responding to clear patient and prescriber demand with products that meet local regulatory standards, offer meaningful choice across formats, and can be supplied reliably at scale - all while reinforcing the level of quality and trust expected from us," said Lana Culley, who heads innovation and international operations at Aurora.

Aurora shares were last seen down US$0.08, to US$3.43 in U.S. pre-market trading.

Related Articles

Research

Research Alert: Xom: A Q1 Beat Despite Middle East Disruption

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:XOM posted Q1 adjusted EPS of $1.16, beating consensus by $0.15, though upstream earnings declined to $5.7B from $6.8B in the prior year, primarily due to lower volumes from divestments and operational disruptions. One-time items of $0.93 mainly reflect mark-to-market accounting that should unwind over coming periods. The company continues advancing structural cost savings, reaching $15.6B or 78% of its $20B target by 2030, while Guyana achieved record production exceeding 900k gross barrels daily and Golden Pass LNG Train 1 reached first production. Management maintains full-year capex guidance of $27B-$29B and buyback guidance of $20B for 2026. XOM allocated $9.2B to shareholder returns versus $6.2B in capex during Q1, suggesting a reinvestment rate of only 43% if this pace continues. The quarterly dividend of $1.03 per share yields 2.7% annually, and we expect continued strong cash returns given the company's advantaged assets in Guyana and the Permian Basin.

$XOM
Research

Research Alert: Linde Q1 Results Beat Expectations Amid Regional Divergence, Project Momentum

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Linde reported Q1 adjusted EPS of $4.33, up 10% Y/Y and $0.06 ahead of consensus, while sales of $8.8B grew 8% Y/Y, beating by 2%. Underlying sales growth of 3% comprised 2% pricing and 1% volume, though adjusted operating margins contracted 10 bps to 30.0%. The results demonstrate management's pricing discipline and ability to execute on the record $7.1B project backlog despite European manufacturing weakness. Management reaffirmed full-year 2026 adjusted EPS guidance of $17.60-$17.90 (7%-9% growth). Americas delivered strong 10% sales growth with margin expansion, while APAC surged 11% with 6% volume growth in electronics. EMEA faced challenges with underlying sales declining 2%. Linde returned $1.5B to shareholders through dividends and repurchases. We believe Linde's backlog-driven growth model supports consistent earnings progression, with project startups accelerating and ROC maintaining at 24%, though margin contraction and volume headwinds limit near-term multiple expansion potential.

$LIN
Mining & Metals

Abasca Resources Closes $2.5 Million Private Placement

Abasca Resources (ABA.V) raised $2.3 million after closing a private placement, the company said Friday.The offering comprises 9 million flow-through common shares priced at $0.25 apiece and 1,250,000 non-flow-through common shares priced at $0.20 each.Abasca plans to use the proceeds to incur Canadian exploration expenses, as well as for general and administrative expenses.The company owns the Key Lake South project, which hosts the Loki Flake graphite deposit, in Saskatchewan.

$ABA.V